Prolongation Of Survival Times Of Terminal Cancer ...[int J Vitam Nutr Res Suppl. 1982] - Pubmed Result
This document was uploaded by user and they confirmed that they have the permission to share it. If you are author or own the copyright of this book, please report to us by using this DMCA report form. Report DMCA
Overview
Download & View Prolongation Of Survival Times Of Terminal Cancer ...[int J Vitam Nutr Res Suppl. 1982] - Pubmed Result as PDF for free.
More details
- Words: 503
- Pages: 1
A service of the U.S. National Library of Medicine and the National Institutes of Health
All Databases
Search
Nucleotide
PubMed
Limits Clear Display All: 1
PubMed
Preview/Index
Protein
Genome
Structure
OMIM
My NCBI [Sign In] [Register] PMC
Journals
Books
History
Clipboard
AbstractPlus
Advanced Search
Go
for Details Show
20
Sort By
Send to
Review: 0 Links
1: Int J Vitam Nutr Res Suppl. 1982;23:103-13.
Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Murata A, Morishige F, Yamaguchi H. Clinical trials administering supplemental ascorbate to terminal cancer patients were conducted at two hospitals in Japan. During the period 1973-1977 there were 99 patients with terminal cancer at the Fukuoka Torikai Hospital. The average times of survival after the date of designation as terminal were 43 days for 44 low-ascorbate patients and 246 days for 55 high-ascorbate patients. Three of the high-ascorbate patients were still alive, their average survival being 1550 days, on April 1, 1980. Similar effectiveness of ascorbate was also observed at the Kamioka Kozan Hospital. There were 31 patients with terminal cancer during the period 1975-1979. The average survival times were 48 days for 19 control patients and 115 days for 6 high-ascorbate patients. One of the high-ascorbate patients was still alive, his survival being 215 days. In addition to the increase in survival times, the administration of large doses of ascorbate seemed to improve the quality of life.
Related Articles Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. [P roc Natl Acad Sci U SA. 1978] Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. [P roc Natl Acad Sci U SA. 1976] Innovation vs. quality control: an 'unpublishable' clinical trial of supplemental ascorbate in incurable cancer. [Me dH ypotheses. 1991] Review Final report of the safety assessment of L-Ascorbic Acid, Calcium Ascorbate, Magnesium Ascorbate, Magnesium Ascorbyl Phosphate, [I nt JT Sodium oxicol. 2005] Review Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate. [P R Hea lth SciJ. 2008] » See Reviews...
|
» See All...
PMID: 6811475 [PubMed - indexed for MEDLINE]
Patient Drug Information Ascorbic Acid (Cecon® Drops, Cenolate® , Cevi-Bid® , ...) Ascorbic acid is used to prevent and treat scurvy, a disease caused by a lack of vitamin C in the body. Source: AHFS Consumer Medication Information
Recent Activity Turn Off
Clear
Prolongation of survival times of terminal cancer patients by administration of large dose... Vitamin C and cancer: an overview. The influence of ascorbic acid on the growth of solid tumors in mice and on tumor control ... Vitamin C lowers mutagenic and toxic effect of hexavalent chromium in guinea pigs. A case-control study of nutrient status and invasive cervical cancer. I. Dietary indicator...
Display
AbstractPlus
Show
20
Sort By
Send to
Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Privacy Statement | Freedom of Information Act | Disclaimer
All Databases
Search
Nucleotide
PubMed
Limits Clear Display All: 1
PubMed
Preview/Index
Protein
Genome
Structure
OMIM
My NCBI [Sign In] [Register] PMC
Journals
Books
History
Clipboard
AbstractPlus
Advanced Search
Go
for Details Show
20
Sort By
Send to
Review: 0 Links
1: Int J Vitam Nutr Res Suppl. 1982;23:103-13.
Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Murata A, Morishige F, Yamaguchi H. Clinical trials administering supplemental ascorbate to terminal cancer patients were conducted at two hospitals in Japan. During the period 1973-1977 there were 99 patients with terminal cancer at the Fukuoka Torikai Hospital. The average times of survival after the date of designation as terminal were 43 days for 44 low-ascorbate patients and 246 days for 55 high-ascorbate patients. Three of the high-ascorbate patients were still alive, their average survival being 1550 days, on April 1, 1980. Similar effectiveness of ascorbate was also observed at the Kamioka Kozan Hospital. There were 31 patients with terminal cancer during the period 1975-1979. The average survival times were 48 days for 19 control patients and 115 days for 6 high-ascorbate patients. One of the high-ascorbate patients was still alive, his survival being 215 days. In addition to the increase in survival times, the administration of large doses of ascorbate seemed to improve the quality of life.
Related Articles Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. [P roc Natl Acad Sci U SA. 1978] Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. [P roc Natl Acad Sci U SA. 1976] Innovation vs. quality control: an 'unpublishable' clinical trial of supplemental ascorbate in incurable cancer. [Me dH ypotheses. 1991] Review Final report of the safety assessment of L-Ascorbic Acid, Calcium Ascorbate, Magnesium Ascorbate, Magnesium Ascorbyl Phosphate, [I nt JT Sodium oxicol. 2005] Review Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate. [P R Hea lth SciJ. 2008] » See Reviews...
|
» See All...
PMID: 6811475 [PubMed - indexed for MEDLINE]
Patient Drug Information Ascorbic Acid (Cecon® Drops, Cenolate® , Cevi-Bid® , ...) Ascorbic acid is used to prevent and treat scurvy, a disease caused by a lack of vitamin C in the body. Source: AHFS Consumer Medication Information
Recent Activity Turn Off
Clear
Prolongation of survival times of terminal cancer patients by administration of large dose... Vitamin C and cancer: an overview. The influence of ascorbic acid on the growth of solid tumors in mice and on tumor control ... Vitamin C lowers mutagenic and toxic effect of hexavalent chromium in guinea pigs. A case-control study of nutrient status and invasive cervical cancer. I. Dietary indicator...
Display
AbstractPlus
Show
20
Sort By
Send to
Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Privacy Statement | Freedom of Information Act | Disclaimer
